Mizuho Securities analyst Salim Syed defended Biogen (NASDAQ: BIIB) amid worries about Spinraza deaths after the FDA made its FAERS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE